Kodiak Plans to Submit BLA for Zenkuda After Phase 3 Data

Kodiak Sciences meets its primary endpoint in a phase 3 trial for its DME drug candidate clearing the way for a regulatory submission; the European Commission approves Roche’s Susvimo for wet AMD; and Merck announces topline results from a pivotal phase 2b/3 trial evaluating two doses of its DME treatment candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices